SVB Leerink Maintains Outperform on Evolus, Raises Price Target to $20
SVB Leerink analyst Marc Goodman maintains Evolus (NASDAQ:EOLS) with a Outperform and raises the price target from $18 to $20.
Why Evolus Shares Are Trading Higher Today
Evolus, Inc. (NASDAQ: EOLS) shares are trading higher after the company issued fourth-quarter and full-year 2022 and announced full-year 2023 revenue guidance.
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+ program members.
Evolus Sees FY23 Revenue $180M-$190M
2023 Outlook and Long-Term Aspirations
"Based on our success to date and a fundamentally strong aesthetic neurotoxin market, we are projecting continued above-market growth for Evolus in 2023,"
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Recap: Evolus Q2 Earnings
Evolus (NASDAQ:EOLS) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell
• Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Evolus’s Earnings: A Preview
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement.
Analysts estimate that Evolus will report an earnings per share (EPS) of $-0.24.
Needham Is Bullish On This Botox Equivalent Aesthetics Company
Needham initiated coverage on Evolus Inc (NASDAQ:EOLS) with a price target of $18.00 (43% upside) and a Buy rating. Evolus is a…
